• 0151 705 3400
  • info@cynapsedx.com

Partnering with CynapseDx

CynapseDx is currently conducting a trial to demonstrate that our assays can save money and resources for any health service by cost effectively identifying patients mis-diagnosed with Parkinson’s disease. This will secure the funding to complete the development of all 3 assays for ß-amyloid, ?-synuclein and phospho-tau. Launch to academics or CRO’s is planned for 2018 with launch of CE marked clinical IVDs in 2019.

Before then, we are interested to partner with pharma to assist stratifying patients based on biomarker levels for improved cohorts for clinical trials.